El interés en corto de CrowdStrike Holdings da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de CrowdStrike Holdings. Los datos de interés en corto se actualizan cada dos semanas.

CrowdStrike Holdings (NASDAQ:CRWD) Bolsa, Informe de interés en corto

CROWDSTRIKE HOLDINGS INC - A

CrowdStrike Holdings

CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.

CrowdStrikeSunnyvale,,California,Us,-,November,16,,2024:,Crowdstrike,Sign,On

News

Movers

CRWD

GOOG

CrowdStrike amplía su alianza con Google Cloud para seguridad en IA. Recibe el premio por excelencia en seguridad de cargas de trabajo.

CrowdStrike (CRWD) amplía su asociación con Google Cloud y gana premio en seguridad

crowdstrike shutter2

Analyst Color

Equities

Large Cap

Upgrades

Price Target

Analyst Ratings

CIBR

LRNZ

CrowdStrike lanza su Programa de Partners de Servicios para impulsar la adopción de su plataforma Falcon SIEM.

Acciones de CrowdStrike (CRWD) suben con el lanzamiento del Programa de Partners y nuevas innovaciones

CrowdStrike (CRWD) se une a Accenture para fortalecer la ciberseguridad y amplía su presencia en ANZ con Dicker Data.

CrowdStrike (CRWD) se asocia con Accenture (ACN) y firma acuerdo con Dicker Data

CrowdStrike Holdings, Inc. - Class A Common Stock

CrowdStrike Holdings Inc

<ul>
<li>Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint</li>
<li>All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes</li>
<li>No serious adverse events considered related to rusfertide were reported</li>
<li>Rusfertide has received Orphan Drug designation and Fast Track designation from the U.S. FDA</li>
</ul>

PTGX

Reported Sunday, Protagonist And Takeda Present 32-Week VERIFY Data: Rusfertide Significantly Reduces Phlebotomy, Improves Symptoms In Polycythemia Vera

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Wall Street expects Campbell&#8217;s Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) to report quarterly earnings at 66 cents per share on revenue of $2.43 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Campbell&#8217;s shares gained 0.6% to $34.24 in after-hours trading.</li>
<li>Analysts expect Science Applications International Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) to post quarterly earnings at $2.13 per share on revenue of $1.87 billion. The company will release earnings before the markets open. SAIC shares rose 0.2% to $115.71 in after-hours trading.</li>
<li>Plus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) posted a net loss of $17.4 million, or $1.19 per share, for the first quarter, versus a year-ago net loss of $3.3 million, or 75 cents per share. Plus Therapeutics shares jumped 34.2% to $0.3851 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced plans to acquire Blueprint Medicines Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) for $9.5 billion. Blueprint Medicines shares fell 1.7% to close at $101.35 on Friday.</li>
<li>Analysts expect Credo Technology Group Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) to post quarterly earnings at 28 cents per share on revenue of $160.16 million after the closing bell. Credo Technology shares gained 0.6% to $61.30 in after-hours trading.</li>
</ul>
Check This Out:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8"> Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Tech

BPMC

CRDO

PSTV

SAIC

Campbell's, SAIC And 3 Stocks To Watch Heading Into Monday

China has refuted U.S. President Donald Trump&#8216;s claims of breaching the Geneva trade agreement, labeling them as unfounded. 
What Happened: On Monday, China's Commerce Ministry rejected Trump's accusations that Beijing had breached the Geneva trade agreement. The ministry confirmed that China had implemented and consistently upheld the agreement reached in Geneva last month, <a href="https://english.news.cn/20250602/ebecebe8437e464da4723ebd20a5e72b/c.html">reported </a>Xinhua News.
The Chinese government stated that the U.S. had &#8220;groundlessly&#8221; accused the nation of breaching the trade deal and pledged to take aggressive measures to protect its interests.
Trump had accused China of breaching a bilateral deal to reduce tariffs. The ministry countered, stating that the U.S. had imposed several &#8220;discriminatory restrictive&#8221; measures against China, such as restricting AI chip exports, banning the sale of chip design software to China and revoking visas for Chinese students. 
&#8220;The U.S. government has unilaterally and repeatedly provoked new economic and trade frictions, exacerbating uncertainty and instability in bilateral economic and trade relations,&#8221; the ministry stated. 
SEE ALSO: <a href="https://benzinga.com/cannabis/25/05/45691518/110m-wiped-out-bitcoin-whale-trader-gets-burned-as-btc-tags-104150" target="_blank" rel="noreferrer noopener">$110M Wiped Out: Bitcoin Whale Trader Gets Burned As BTC Tags $104,150 &#8211; Benzinga</a>
Why It Matters: This recent dispute follows a series of events that have strained U.S.-China trade relations. On Friday, President Trump accused China of violating an agreement to ease tariffs. Analysts suggest China&#8217;s delay in approving rare earth export licenses, over which it holds strategic control, may have fueled Trump&#8217;s anger, even though he didn&#8217;t directly mention them in his accusations, reported the South China Morning Post.
Following the development. the U.S.-listed Chinese stocks, including Baidu, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) and Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45703311/us-listed-chinese-stocks-drop-after-trump-renews-trade-tensions">dropped</a> 2.95% and 2.85%, respectively.
A day prior to that, China called on the U.S. to completely <a href="https://www.benzinga.com/markets/25/05/45664337/china-tells-us-to-entirely-revoke-wrongful-unilateral-tariffs-after-court-blocks-trumps-liberation-day-levies">withdraw </a>the unilateral tariff measures when a U.S. federal court blocked Trump tariffs which have now been temporarily reinstated.
Meanwhile, U.S. Treasury Secretary Scott Bessent indicated that trade negotiations between the two countries had reached a <a href="https://www.benzinga.com/25/05/45685544/scott-bessent-says-us-china-trade-talks-at-stalemate-need-trump-and-xi-jinping-touch-to-break-the-deadlock">stalemate</a>. On Sunday, Bessent stated in an interview with CBS news that he is confident President Trump and Chinese President Xi Jinping would meet &#8220;soon&#8221; and iron out the differences. 
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/cannabis/25/06/45714198/elon-musks-kekius-maximus-gameplay-sends-these-namesake-coins-surging" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s &#8216;Kekius Maximus&#8217; Gameplay Sends These Namesake Coins Surging &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

BABA

BIDU

Xi Jinping's China Dismisses Trump's 'Groundless' Accusations On Geneva Trade Deal Breach, Vows Strong Retaliation

Scott Bessent, the U.S. Treasury Secretary, assured that the country will not default on its debt, even as the deadline for raising the federal debt ceiling approaches.
What Happened: Bessent, in an interview with CBS&#8217;s Face the Nation on Sunday, dismissed the possibility of a default. &#8220;The United States of America is never going to default. That is never going to happen,&#8221; he said, <a href="https://www.cbsnews.com/news/scott-bessent-treasury-secretary-face-the-nation-06-01-2025/">reported</a> CBS News.
The debt ceiling, a cap set by Congress on the amount of debt the federal government can legally borrow, is a contentious issue. Republican leaders have linked the debt limit increase to President&nbsp;Donald Trump&#8216;s tax and spending bill, adding complexity to the negotiations over the legislation.
Bessent did not reveal the &#8220;X date&#8221; — the moment when the Treasury exhausts its cash and special accounting maneuvers that help it remain under the debt ceiling while continuing to meet federal obligations on time. He explained that this information is used to advance the bill.
He also responded to a warning from Jamie Dimon, CEO of JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), regarding a possible disruption in the bond market. Bessent said, &#8220;I've known Jamie for a long time, and for his entire career he's made predictions like this. Fortunately none of them have come true.&#8221; 
<path fill-rule="evenodd" clip-rule="evenodd" d="M7 5C7 3.34315 8.34315 2 10 2H19C20.6569 2 22 3.34315 22 5V14C22 15.6569 20.6569 17 19 17H17V19C17 20.6569 15.6569 22 14 22H5C3.34315 22 2 20.6569 2 19V10C2 8.34315 3.34315 7 5 7H7V5ZM9 7H14C15.6569 7 17 8.34315 17 10V15H19C19.5523 15 20 14.5523 20 14V5C20 4.44772 19.5523 4 19 4H10C9.44772 4 9 4.44772 9 5V7ZM5 9C4.44772 9 4 9.44772 4 10V19C4 19.5523 4.44772 20 5 20H14C14.5523 20 15 19.5523 15 19V10C15 9.44772 14.5523 9 14 9H5Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M12.1318 2.50389C12.3321 2.15338 12.7235 1.95768 13.124 2.00775L13.5778 2.06447C16.0449 2.37286 17.636 4.83353 16.9048 7.20993L16.354 8.99999H17.0722C19.7097 8.99999 21.6253 11.5079 20.9313 14.0525L19.5677 19.0525C19.0931 20.7927 17.5124 22 15.7086 22H6C4.34315 22 3 20.6568 3 19V12C3 10.3431 4.34315 8.99999 6 8.99999H8C8.25952 8.99999 8.49914 8.86094 8.6279 8.63561L12.1318 2.50389ZM10 20H15.7086C16.6105 20 17.4008 19.3964 17.6381 18.5262L19.0018 13.5262C19.3488 12.2539 18.391 11 17.0722 11H15C14.6827 11 14.3841 10.8494 14.1956 10.5941C14.0071 10.3388 13.9509 10.0092 14.0442 9.70591L14.9932 6.62175C15.3384 5.49984 14.6484 4.34036 13.5319 4.08468L10.3644 9.62789C10.0522 10.1742 9.56691 10.5859 9 10.8098V19C9 19.5523 9.44772 20 10 20ZM7 11V19C7 19.3506 7.06015 19.6872 7.17071 20H6C5.44772 20 5 19.5523 5 19V12C5 11.4477 5.44772 11 6 11H7Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M11.8727 21.4961C11.6725 21.8466 11.2811 22.0423 10.8805 21.9922L10.4267 21.9355C7.95958 21.6271 6.36855 19.1665 7.09975 16.7901L7.65054 15H6.93226C4.29476 15 2.37923 12.4921 3.0732 9.94753L4.43684 4.94753C4.91145 3.20728 6.49209 2 8.29589 2H18.0045C19.6614 2 21.0045 3.34315 21.0045 5V12C21.0045 13.6569 19.6614 15 18.0045 15H16.0045C15.745 15 15.5054 15.1391 15.3766 15.3644L11.8727 21.4961ZM14.0045 4H8.29589C7.39399 4 6.60367 4.60364 6.36637 5.47376L5.00273 10.4738C4.65574 11.746 5.61351 13 6.93226 13H9.00451C9.32185 13 9.62036 13.1506 9.8089 13.4059C9.99743 13.6612 10.0536 13.9908 9.96028 14.2941L9.01131 17.3782C8.6661 18.5002 9.35608 19.6596 10.4726 19.9153L13.6401 14.3721C13.9523 13.8258 14.4376 13.4141 15.0045 13.1902V5C15.0045 4.44772 14.5568 4 14.0045 4ZM17.0045 13V5C17.0045 4.64937 16.9444 4.31278 16.8338 4H18.0045C18.5568 4 19.0045 4.44772 19.0045 5V12C19.0045 12.5523 18.5568 13 18.0045 13H17.0045Z" fill="currentColor"></path>
<path d="M2.5 5.5C4.3 5.2 5.2 4 5.5 2.5C5.8 4 6.7 5.2 8.5 5.5C6.7 5.8 5.8 7 5.5 8.5C5.2 7 4.3 5.8 2.5 5.5Z" fill="currentColor" stroke="currentColor" stroke-linecap="round" stroke-linejoin="round"></path>
<path d="M5.66282 16.5231L5.18413 19.3952C5.12203 19.7678 5.09098 19.9541 5.14876 20.0888C5.19933 20.2067 5.29328 20.3007 5.41118 20.3512C5.54589 20.409 5.73218 20.378 6.10476 20.3159L8.97693 19.8372C9.72813 19.712 10.1037 19.6494 10.4542 19.521C10.7652 19.407 11.0608 19.2549 11.3343 19.068C11.6425 18.8575 11.9118 18.5882 12.4503 18.0497L20 10.5C21.3807 9.11929 21.3807 6.88071 20 5.5C18.6193 4.11929 16.3807 4.11929 15 5.5L7.45026 13.0497C6.91175 13.5882 6.6425 13.8575 6.43197 14.1657C6.24513 14.4392 6.09299 14.7348 5.97903 15.0458C5.85062 15.3963 5.78802 15.7719 5.66282 16.5231Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></path>
<path d="M14.5 7L18.5 11" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></path> 
<path d="M3.06957 10.8763C3.62331 6.43564 7.40967 3 12 3C14.2824 3 16.4028 3.85067 18.0118 5.25439V4C18.0118 3.44772 18.4595 3 19.0118 3C19.5641 3 20.0118 3.44772 20.0118 4V8C20.0118 8.55228 19.5641 9 19.0118 9H15C14.4477 9 14 8.55228 14 8C14 7.44772 14.4477 7 15 7H16.9571C15.6757 5.76379 13.9101 5 12 5C8.43108 5 5.48466 7.67174 5.0542 11.1237C4.98586 11.6718 4.48619 12.0607 3.93815 11.9923C3.39011 11.924 3.00123 11.4243 3.06957 10.8763ZM20.0618 12.0077C20.6099 12.076 20.9988 12.5757 20.9304 13.1237C20.3767 17.5644 16.5903 21 12 21C9.72322 21 7.60762 20.1535 5.99999 18.7559V20C5.99999 20.5523 5.55228 21 4.99999 21C4.44771 21 3.99999 20.5523 3.99999 20V16C3.99999 15.4477 4.44771 15 4.99999 15H8.99999C9.55228 15 9.99999 15.4477 9.99999 16C9.99999 16.5523 9.55228 17 8.99999 17H7.04285C8.32433 18.2362 10.0899 19 12 19C15.5689 19 18.5153 16.3283 18.9458 12.8763C19.0141 12.3282 19.5138 11.9393 20.0618 12.0077Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M5.29289 9.29289C5.68342 8.90237 6.31658 8.90237 6.70711 9.29289L12 14.5858L17.2929 9.29289C17.6834 8.90237 18.3166 8.90237 18.7071 9.29289C19.0976 9.68342 19.0976 10.3166 18.7071 10.7071L12.7071 16.7071C12.5196 16.8946 12.2652 17 12 17C11.7348 17 11.4804 16.8946 11.2929 16.7071L5.29289 10.7071C4.90237 10.3166 4.90237 9.68342 5.29289 9.29289Z" fill="currentColor"></path>
SEE ALSO:&nbsp;<a href="https://benzinga.com/cannabis/25/06/45713593/trump-shares-baseless-theory-about-bidens-alleged-execution-and-subsequent-robotic-replacement-in-2020" target="_blank" rel="noreferrer noopener">Trump Shares Baseless Theory About Biden&#8217;s Alleged Execution And Subsequent Robotic Replacement In 2020</a>
Why It Matters: The assurance from Bessent comes amid warnings from financial experts.&nbsp;<a href="https://www.benzinga.com/markets/economic-data/25/05/45704089/jamie-dimon-warns-of-bond-market-crisis-caused-by-us-debt-binge-youre-going-to-panic">Jamie Dimon</a> had recently warned of a potential crisis in the bond market due to unchecked debt and monetary expansion. Similarly, former Treasury Secretary&nbsp;<a href="https://www.benzinga.com/markets/25/05/45686699/larry-summers-issues-stark-warning-the-big-beautiful-bill-is-actually-a-prescription-for-deadly-dangerous-decline">Larry Summers</a>&nbsp;had criticized the lack of fiscal discipline in current Republican proposals, warning of a potential crisis if current debt trends continue. 
The statements from Bessent are crucial in maintaining investor confidence amid these criticisms. 
Meanwhile, the Treasury Secretary also ruled out apprehensions about inflation. "Actually, the inflation numbers are the best in four years. So why don't we stop trying to say this could happen, and wait and see what does happen,&#8221; stated Bessent.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/cannabis/25/06/45713578/jerome-powell-to-step-down-x-abuzz-with-rumors-but-polymarket-bettors-are-not-buying-it" target="_blank" rel="noreferrer noopener">Jerome Powell To Step Down? X Abuzz With Rumors, But Polymarket Bettors Are Not Buying It &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

US 'Never Going To Default,' Says Scott Bessent, Dismissing Jamie Dimon's Debt Crisis Warnings: 'For His Entire Career…'

Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) Co-Founder Joe Lonsdale delivered sharp criticism of America&#8217;s healthcare system during the Reagan National Economic Forum, calling for artificial intelligence adoption and regulatory reform to combat rising costs and China&#8217;s growing biotechnology dominance.
What Happened: Speaking on CNBC, Lonsdale outlined a two-pronged crisis threatening U.S. healthcare leadership. On the biotechnology front, China has captured 30% of the global biotech market in just five years, leveraging regulatory speed advantages to undercut American innovation. 
&#8220;They take a company we started a year or two ago, go after the same target, get through their regulators faster and then sell it back to our pharma companies,&#8221; Lonsdale said, citing the FDA&#8217;s decade-long approval timelines as a critical competitive disadvantage.
The venture capitalist emphasized that China&#8217;s biotechnology surge combines legitimate innovation with intellectual property theft. This dynamic discourages U.S. investment in certain therapeutic areas where regulatory delays create vulnerability to foreign competition.
See Also: <a href="https://www.benzinga.com/markets/market-summary/25/06/45713715/dow-futures-slip-over-100-points-after-trump-announces-doubling-steel-tariffs-nikkei-down" target="_blank" rel="noreferrer noopener">Dow Futures Slip Over 100 Points After Trump Announces Doubling Steel Tariffs, Nikkei Down</a>
Why It Matters: Healthcare services represent the second battleground, with Lonsdale describing city-based hospital systems as &#8220;effectively cartels&#8221; that block competition through state-level legislation. These barriers prevent new provider networks and limit patient data portability, driving up costs across the healthcare economy.
Current healthcare inflation threatens national fiscal stability, with unfunded Medicare and Medicaid obligations. &#8220;If that keeps going up 6-7% a year, no one&#8217;s going to get healthcare except for maybe the rich,&#8221; Lonsdale warned, noting healthcare&#8217;s resistance to broader deflationary trends.
Lonsdale praised Elon Musk&#8217;s Department of Government Efficiency (DOGE) efforts, noting the program cut approximately $150-160 billion annually before Musk&#8217;s departure. He calculated that this represents $3 trillion in equity value based on the government&#8217;s cost of capital. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Palantir Co-Founder Joe Lonsdale on the growing important of AI in defense" width="500" height="281" src="https://www.youtube.com/embed/3zlOYet-cqA?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45713895/bitcoin-ethereum-dogecoin-hold-steady-amid-us-china-trade-war-tensions-analyst-foresees-big-party-if-btc-reclaims-106000" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Hold Steady Amid US-China Trade War Tensions: Analyst Foresees ‘Big Party' If BTC Reclaims $106,000</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: PeopleImages.com &#8211; Yuri A On Shutterstock.com

Health Care

PLTR

Joe Lonsdale Slams Healthcare 'Cartels:' Urges AI, Regulatory Reform To Slash Costs, Reclaim Biotech From China

Highlights of the REZILIENT1 Phase 1/2 trial in the authors' conclusions include:
<ul>
<li>Zipalertinib demonstrated clinically meaningful efficacy in the primary efficacy population (n=176), including 51 patients who had received prior amivantamab.</li>
<li>The confirmed objective response rate (ORR) was 35.2% overall, and median duration of response (mDOR) and progression-free survival were 8.8 months and 9.4 months, respectively.</li>
<li>In patients treated after prior platinum-based chemotherapy only (n=125), ORR was 40% with mDOR of 8.8 months.</li>
<li>The safety profile of zipalertinib was manageable and consistent with previously reported data.¹</li>
<li>In exploratory subgroup analyses:
<ul>
<li>Patients who had received prior&nbsp;amivantamab without other ex20ins-targeted therapy showed a confirmed ORR of 30% and mDOR of 14.7 months.</li>
<li>Patients with brain metastases showed a confirmed&nbsp;ORR of 30.9% and a mDOR of 8.3 months</li>
</ul>
</li>
</ul>

CGEM

TAIHF

Reported Sunday, Taiho And Cullinan's Zipalertinib Shows 40% ORR In Platinum-Treated EGFR ex20ins NSCLC, REZILIENT1 Results Published In JCO

Reported Saturday, Tempus Unveils Fuses Program To Transform Precision Medicine With AI-Powered Diagnostic Models And Multimodal Data At Scale

<ul>
<li>TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca's DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC</li>
<li>TROPION-Lung02 results include first exploratory QCS analysis of DATROWAY in first-line setting</li>
<li>NeoCOAST-2 phase 2 results continue to show potential for DATROWAY plus durvalumab and single-agent platinum chemotherapy in neoadjuvant setting</li>
</ul>

DSNKY

Reported Sunday, AstraZeneca's DATROWAY Shows Over 55% Response Rate In First-Line Advanced NSCLC In TROPION-Lung02 Phase 1b Trial With Immunotherapy Combinations

<ul>
<li>Two-thirds (67.4%) of patients treated with IMFINZI-based perioperative regimen remained event-free at two years</li>
<li>First and only immunotherapy to demonstrate statistically significant event-free survival in a global Phase III trial in this setting</li>
</ul>

Reported Sunday, AstraZeneca's IMFINZI Regimen Reduces Risk Of Progression, Recurrence, Or Death By 29% In Early Gastric Cancer In Phase 3 MATTERHORN Trial

First pivotal trial to demonstrate clinical value of monitoring circulating tumor DNA to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer
First and only next-generation oral SERD and complete ER antagonist to demonstrate consistent progression-free survival benefit in combination with widely approved CDK4/6 inhibitors in 1st-line advanced breast cancer

Reported Sunday, AstraZeneca's Camizestrant Reduces Risk Of Progression Or Death By 56% In HR+ Advanced Breast Cancer With ESR1 Mutation In SERENA-6 Trial

Campbell's Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) will release its third-quarter earnings results before the opening bell on <a href="https://www.benzinga.com/quote/cpb/earnings">Monday, June 2.</a>
Analysts expect the Camden, New Jersey-based company to report quarterly earnings at 66 cents per share, down from 75 cents per share in the year-ago period. Campbell's projects to report quarterly revenue of $2.43 billion. Compare that to the $2.37 billion it reported last year, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 5, the company reported second-quarter sales growth of 9% to $2.685 billion, missing the analyst consensus estimate of $2.74 billion.
Campbell's shares fell 0.4% to close at $34.04 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/cpb/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Wells Fargo analyst Chris Carey maintained an Equal-Weight rating and slashed the price target from $40 to $34 on May 30, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Piper Sandler analyst Michael Lavery maintained an Overweight rating and cut the price target from $45 to $42 on May 23, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Morgan Stanley analyst Megan Alexander initiated coverage on the stock with an Equal-Weight rating and a price target of $40 on March 24, 2025. This analyst has an accuracy rate of 70%.</li>
<li>JP Morgan analyst Ken Goldman downgraded the stock from Overweight to Neutral and cut the price target from $48 to $37 on March 6, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Jefferies analyst Rob Dickerson maintained a Hold rating and slashed the price target from $42 to $40 on March 5, 2025. This analyst has an accuracy rate of 66%</li>
</ul>
Considering buying CPB stock? Here&#8217;s what analysts think:
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Earnings

Pre-Market Outlook

Trading Ideas

Top Wall Street Forecasters Revamp Campbell's Expectations Ahead Of Q3 Earnings

<ul>
<li>Daiichi Sankyo and AstraZeneca's ENHERTU demonstrated a median overall survival of 14.7 months</li>
<li>Results reinforce second-line use of ENHERTU globally in this setting</li>
</ul>

Reported Saturday, Daiichi Sankyo And AstraZeneca's ENHERTU Demonstrates 14.7-Month Median OS And 30% Reduction In Risk Of Death In HER2+ Gastric Cancer

New five-year agreement delivers critical academic and life sciences insights into more than 400 institutions, broadening access and driving national research excellence

CLVT

Clarivate And CAPES Sign Five-Year Agreement To Broaden Access To Trusted Academic And Life Sciences Tools Across Brazil

On Sunday, Sen. Elizabeth Warren (D-Mass.) doubled down on her accusations that Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk benefited from Donald Trump's <a href="https://www.benzinga.com/25/03/44183216/elizabeth-warren-wants-to-know-from-elon-musk-mark-zuckerberg-and-jeff-bezos-how-much-they-spent-lobbying-for-potential-windfall-accuses-tech-giants-of-cozying-up-up-to-trump-admini">sweeping tariffs</a>, calling for a federal investigation into what she labeled "textbook corruption."
What Happened: In a video posted on social media, Warren alleged that Starlink, Musk's satellite internet venture, received favorable foreign operating permits around the same time Trump imposed broad tariffs during trade negotiations.
"Suddenly, some of the same countries that were negotiating trade deals with Trump started giving Starlink some pretty good deals," Warren said, citing <a href="https://www.benzinga.com/news/global/25/05/45537805/musks-starlink-could-sidestep-south-african-equity-rules-under-deal-aimed-at-calming-relations-ahead-of-trump-meeting-report">new Starlink permits</a> in Gambia, Bangladesh, Vietnam and India.
See Also:&nbsp;<a href="https://www.benzinga.com/media/25/05/45664231/teslas-optimus-may-be-the-first-humanoid-robot-to-achieve-high-volume-and-tech-scale-says-nvidia-ceo-jensen-huang-likely-to-be-the-next-multi-trillion-dollar-industry" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Optimus May Be The First Humanoid Robot To Achieve High Volume And Tech Scale, Says Nvidia CEO Jensen Huang: ‘… Likely To Be The Next Multi-Trillion Dollar Industry&#8217;</a>
"Is Elon Musk using international trade negotiations as leverage to make even more and more and more money for himself?" she asked. "Looks like textbook corruption."
Warren warned that &#8220;Elon Musk is cashing in on Donald Trump&#8217;s tariffs,&#8221; while everyone else is paying for this chaos, referring to the consumer impact of higher import prices.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Did Elon Musk use Trump's tariffs as leverage to make more and more money for himself?   I called for an investigation, because while Elon is cashing in, everyone else is paying for this chaos. We all deserve answers. <a href="https://t.co/4cKv0f3VCJ">pic.twitter.com/4cKv0f3VCJ</a>
&mdash; Elizabeth Warren (@SenWarren) <a href="https://twitter.com/SenWarren/status/1929230259246834061?ref_src=twsrc%5Etfw">June 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
SpaceX did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga's</a> request for comments.
Why It's Important: Last month, Senate Democrats, including Warren, urged a federal <a href="https://www.benzinga.com/general/space/25/05/45430526/as-elon-musk-secures-saudi-starlink-deal-elizabeth-warren-and-senate-democrats-demand-probe-into-possible-ethics-violations-and-accuse-trump-administration-of-helping-spacex-secure-foreign-deals">probe into whether</a> Trump's administration is helping SpaceX gain entry into international markets.
This demand followed Musk's announcement at the Saudi-U.S. Investment Forum that Saudi Arabia has authorized Starlink services for use in the aviation and maritime sectors.
Previously, The Washington Post reported that state department cables showed that U.S. embassies and the department consistently encouraged tariff-affected <a href="https://www.benzinga.com/tech/25/05/45316049/us-reportedly-pressures-tariff-hit-nations-to-approve-elon-musks-starlink-an-important-lubricant-that-facilitates-a-deal">countries to ease restrictions</a> on satellite firms, often highlighting Starlink by name.
In April, senate democratic committee staffers released a report alleging that Musk could <a href="https://www.benzinga.com/25/04/45058801/elon-musks-doge-influence-could-help-his-companies-avoid-over-2-billion-in-potential-liabilities-senate-report">potentially bypass over $2 billion</a> in financial obligations due to his sway within the U.S. government.
Price Action: Tesla stock dropped 3.34% on Friday, finishing the day at $346.46. It slipped a further 0.27% in after-hours trading. So far this year, the stock is down 8.65%, based on <a href="http://pro.benzinga.com/">Benzinga Pro data</a>.
According to Benzinga Edge Stock Rankings, Tesla holds an impressive growth score of 91.89%. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Click here to see how it measures up against other top-performing stocks</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02024321/Screenshot-2025-06-02-at-9.59.43%E2%80%AFAM-1.png" alt="" class="wp-image-934603" /></a></figure>
Photo: Shutterstock/Sheila Fitzgerald
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45396297/cathie-wood-dumps-palantir-as-stock-touches-peak-prices-bails-on-soaring-flying-taxi-maker-archer-aviation" target="_blank" rel="noreferrer noopener">Cathie Wood Dumps Palantir As Stock Touches Peak Prices, Bails On Soaring Flying-Taxi Maker Archer Aviation</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

TSLA

Elizabeth Warren Calls It 'Textbook Corruption,' Once Again Asks For Probe Into Elon Musk 'Cashing In' On Trump Tariffs

Colt, Honeywell and Nokia join forces to trial space-based quantum-safe cryptography
<ul>
<li>Tech collaboration will explore ways to protect encrypted data from quantum risk using Low Earth Orbit satellites.</li>
<li>Trial to use space-based quantum key distribution to overcome terrestrial distance limitations.</li>
</ul>

CZGZF

Colt, Honeywell, And Nokia Collaborate On Space-Based Quantum-Safe Cryptography Using Low Earth Orbit Satellites

<ul>
<li>MaxLinear G.hn Technology enables Comtrend's powerline data modules to accelerate EV charger installations</li>
</ul>

MaxLinear And Comtrend Unveil EV Charging Station Modules Using G.hn For Real-Time, Reliable Data Over Existing Powerlines

<ul>
<li>RP1 plus nivolumab generated robust responses in both injected and non-injected lesions.</li>
<li>Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were generally well tolerated.</li>
</ul>

REPL

Reported Sunday, Replimune Reports 32.9% ORR With RP1 Plus Nivolumab In Anti-PD1 Failed Melanoma At ASCO, With Deep Organ Injections Showing Higher Response Rates

Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) executive chairman Michael Saylor expressed interest Saturday in discussing Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) with popular podcaster Joe Rogan.
What Happened:&nbsp;In an X post, Saylor wrote, &#8220;Hey Joe Rogan, let&#8217;s talk about Bitcoin.&#8221;
The comment came in response to a fan-run account&#8217;s question to X users about who they&#8217;d like to see Rogan interview that he hasn&#8217;t before.
Rogan, one of the world&#8217;s most successful podcasters, has interviewed influential figures like tech mogul&nbsp;Elon Musk, boxing legend&nbsp;Mike Tyson and President&nbsp;Donald Trump on his "The Joe Rogan Experience" show. As of this writing, his YouTube channel has nearly 20 million subscribers.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Hey <a href="https://twitter.com/joerogan?ref_src=twsrc%5Etfw">@JoeRogan</a>, let&#39;s talk about Bitcoin.
&mdash; Michael Saylor (@saylor) <a href="https://twitter.com/saylor/status/1928931268852412704?ref_src=twsrc%5Etfw">May 31, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In other news, Saylor hinted on X that his firm Strategy would continue to pile on BTC in the coming week. 
&#8220;Orange is my Preferred Color,&#8221; he wrote,<a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45188974/michael-saylor-hints-more-btc-purchases-on-the-way-as-mstr-surges-47-in-a-month-too-much-blue-not-enough-orange"> typical of his Sunday posts</a> which have almost always preceded Bitcoin purchases the following Monday.
As of this writing, Strategy's Bitcoin stockpile has grown to 580,250 BTC, worth nearly $61 billion, with an unrealized profit of 50%,&nbsp;<a href="https://bitcointreasuries.net/" target="_blank" rel="noreferrer noopener">according&nbsp;</a>to&nbsp;&nbsp;bitcointreasuries.com.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Orange is my Preferred Color <a href="https://t.co/rc9JIcJOAT">pic.twitter.com/rc9JIcJOAT</a>
&mdash; Michael Saylor (@saylor) <a href="https://twitter.com/saylor/status/1929152786186301755?ref_src=twsrc%5Etfw">June 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://benzinga.com/cannabis/25/06/45713578/jerome-powell-to-step-down-x-abuzz-with-rumors-but-polymarket-bettors-are-not-buying-it" target="_blank" rel="noreferrer noopener">Jerome Powell To Step Down? X Abuzz With Rumors, But Polymarket Bettors Are Not Buying It</a>
Why It Matters:&nbsp;The proposed discussion holds significance in light of Rogan&#8217;s known interest in Bitcoin. The podcast host has previously <a href="https://www.benzinga.com/markets/cryptocurrency/23/10/35139978/joe-rogan-tells-sam-altman-that-bitcoin-can-become-a-universal-viable-currency-admits-cbdc" target="_blank" rel="noreferrer noopener">called Bitcoin the &#8220;real fascinating cryptocurrency</a>&#8221; and one with the most likelihood of becoming a &#8220;universal viable currency.&#8221;
In fact, back in April 2014, <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42229486/joe-rogans-bitcoin-pile-has-grown-over-30000-in-value-but-he-hasnt-sold-conviction-based-hodling-or-has-the-podcast-king-lost-his-keys">Rogan publicly shared details</a> of his Bitcoin address, which as of this writing has a balance of 5.243 BTC, translating to $550,362.
Price Action:&nbsp; At the time of writing, Bitcoin was exchanging hands at $104,971, up 0.52% in the last 24 hours, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.&nbsp;
Shares of Strategy closed 0.39% closer at $369.20 during Friday&#8217;s regular session. The stock has returned over 27% year-to-date.
MSTR exhibited a very high momentum score—a measure of the stock&#8217;s relative strength based on its price movement patterns and volatility over multiple timeframes—as of this writing. Visit <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">Benzinga Edge Stock Rankings</a>. to view the top ten stocks with the highest momentum scores.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="517" height="200" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02024043/Screenshot-2025-06-02-121027.png" alt="" class="wp-image-934601" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02024043/Screenshot-2025-06-02-121027.png 517w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02024043/Screenshot-2025-06-02-121027-300x116.png 300w" sizes="(max-width: 517px) 100vw, 517px" /></a></figure>
Photo Courtesy: Rokas Tenys on Shutterstock.com
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://benzinga.com/crypto/cryptocurrency/25/06/45712312/michael-saylor-called-scaramucci-from-a-yacht-and-it-changed-the-ending-of-his-book" target="_blank" rel="noreferrer noopener">Michael Saylor Called Scaramucci From a Yacht and It Changed the Ending of His Book</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

Michael Saylor Asks Joe Rogan For A Chat: 'Let's Talk About Bitcoin'

<ul>
<li>Data Highlights Transformative Promise of CAR T in Solid Tumors</li>
<li>Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC
<ul>
<li>A Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate</li>
<li>Four of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months</li>
</ul>
</li>
<li>Robust Expansion, Persistence, and Tumor Infiltration of ALLO-316 Seen with Standard Lymphodepletion, Showcasing Dagger&#xAE; Technology as a Next-Generation Allogeneic Platform</li>
<li>Phase 1 Safety Profile was Manageable; Proactive Diagnostic and Management Strategies Proved Effective in Mitigating IEC-HS While Preserving Efficacy</li>
</ul>

ALLO

Reported Sunday, Allogene Reports 31% Confirmed Response Rate With ALLO-316 In CD70-High RCC Patients At ASCO, With Durable Remissions And Manageable Safety

Chinese EV giant BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) is reportedly facing backlash for its aggressive discounts that have triggered a price war in the fiercely contested EV market in China.
What Happened: BYD's stock fell over 5% on the Hong Kong exchange following last week's 15% plunge, due to reports that the price war had caught Beijing's attention, Bloomberg reported <a href="https://www.bloomberg.com/news/articles/2025-06-01/byd-may-sales-highest-this-year-after-week-of-steep-discounts">on</a> Sunday.
The Chinese Communist Party&#8217;s (CCP) newspaper, The People's Daily, slammed the "rat race" in the domestic EV sector, which it said could hurt domestic supply chains and damage the "Made in China" reputation. However, it did not name any specific companies, the report said.
The report also mentioned that China's automobile association criticized the price war, which could impact the sector's growth and bring about quality issues, while China's Ministry of Industry and Information Technology agreed with the stance.
Why It Matters: The news comes in as China's EV price war has led to an intense competition in the country among EV manufacturers offering <a href="https://www.benzinga.com/25/01/42761825/ev-price-war-heats-up-as-chinese-automakers-extend-subsidies">aggressive discounts</a> to drive up sales.
Interestingly, BYD and other Chinese players are bolstering their presence in markets outside of China, with BYD already surpassing Elon Musk's Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) <a href="https://www.benzinga.com/25/05/45564693/byd-outsells-elon-musks-tesla-amid-european-plans-shift-into-gear">in European sales </a>as the company is offering the Euro-spec version of its <a href="https://www.benzinga.com/markets/25/05/45560953/byds-europe-pivot-in-full-swing-with-new-26000-affordable-ev-amid-tesla-sal">best-selling EV hatchback</a> in the region for $26,000.
On the flip side, a major BYD dealer in China has reportedly <a href="https://www.benzinga.com/25/05/45666513/a-major-byd-dealer-in-china-shut-down-its-operations-as-ev-giant-expands-into-europe-report">closed down over 20 dealerships </a>in the country across 4 major cities, citing what the dealer said were policy changes by the automaker that impacted the company's cash flow.
Elsewhere, experts like Future Fund LLC's Gary Black indicate that BYD's price war <a href="https://www.benzinga.com/general/travel/25/05/45611551/gary-black-says-price-war-by-byd-threatens-tesla-dismisses-elon-musks-comeback-as-non-event">could threaten Tesla's position</a> in the country.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45639357/teslas-chinese-rival-byd-sued-for-45-million-over-alleged-human-trafficking-slave-like-conditions-at-brazil-factory-site">Tesla&#8217;s Chinese Rival BYD Sued For $45 Million Over Alleged Human Trafficking, Slave-Like Conditions At Brazil Factory Site</a></li>
</ul>
Photo courtesy: Tada Images / Shutterstock.com

Comments

CrowdStrike Holdings

Interés en corto

CrowdStrike Holdings (NASDAQ:CRWD) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL